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Open access underPurpose: To present an interim analysis of the trial comparing two neoadjuvant therapies for unresec-
table rectal cancer.
Methods: Patients with ﬁxed cT3 or cT4 or locally recurrent rectal cancer without distant metastases
were randomized to either 5  5 Gy and 3 courses of FOLFOX4 (schedule I) or 50.4 Gy delivered in 28
fractions given simultaneously with 5-Fu, leucovorin and oxaliplatin (schedule II). Surgery in both groups
was performed 12 weeks after the beginning of radiation and 6 weeks after neoadjuvant treatment.
Results: 49 patients were treated according to schedule I and 48 according to schedule II. Grade III+ acute
toxicity was observed in 26% of patients in group I and in 25% in group II. There were two toxic deaths,
both in group II. The microscopically radical resection (primary endpoint) rate was 73% in group I and 71%
in group II. Overall and severe postoperative complications were recorded in 27% and 9% of patients vs.
16% and 7%, respectively. Pathological complete response was observed in 21% of the patients in group I
and in 9% in group II.
Conclusions: The interim analysis revealed no major differences in acute toxicity and local efﬁcacy
between the two evaluated strategies.
 2013 Elsevier Ireland Ltd. Radiotherapy and Oncology 107Open access under CC BY-NC-ND license. 
(2013)171–177An unresectable primary tumour is commonly deﬁned as a pal-
pably ﬁxed lesion involving adjacent organs or structures. It is
diagnosed in approximately 15% of patients with rectal cancerd chemoradiation with
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 CC BY-NC-ND license. a 6–8 week interval to surgery is the standard treatment for this
group of patients [2]. Chemoradiation aims for tumour shrinkage
to allow radical resection. The most frequently used scheme of
neoadjuvant chemoradiation involves delivering 45 Gy or 50.4 Gy
given in 1.8 Gy per fraction concomitantly with 5-ﬂuorouracil
and leucovorin or with capecytabine. The results of such treatment
are not satisfactory; the tumour remains unresectable in about 15%
of patients, the rate of radical resection is approximately 75%, and
5-year survival is approximately 50% [1,2]. Therefore, there is a
need for exploring more effective schedules of neoadjuvant
172 Neoadjuvant treatment for unresectable rectal cancertreatment. A retrospective study has suggested that an addition of
oxaliplatin to ﬂuoropyrimidine-based chemoradiation increases
efﬁcacy [3].
Polish and Australian randomized studies have compared short-
course preoperative radiation (5  5 Gy) and immediate surgery
with conventionally fractionated preoperative chemoradiation
and delayed surgery in patients with resectable rectal cancer
[4,5]. Both trials have shown no difference in long-term results be-
tween the two treatment-assigned groups. A randomized study
comparing conventionally fractionated radiotherapy and simulta-
neously delivered chemotherapy with conventionally fractionated
radiotherapy alone conducted in patients with unresectable cancer
has demonstrated beneﬁt in the combined modality group [2].
Based on these three randomized trials, it has been hypothesized
that if the interval between short-course radiation and surgery in-
creases allowing for tumour shrinkage [6–11], and if consolidation
chemotherapy is added to short-course radiation in a tight se-
quence providing an additional cell killing effect, such a combina-
tion may be superior to conventionally fractionated
chemoradiation. Published data have supported such a concept in
both unresectable and resectable rectal cancer [11–15]. It should
be noted that chemotherapy and short-course radiation cannot
be delivered simultaneously due to an apprehension of unaccept-
able acute toxicity; thus, only sequential treatment is possible.
The aim of our randomized trial is to test the above hypothesis.
Here we present an interim analysis of this trial.Material and methods
The trial was approved by an ethics committee. Unresectable
rectal cancer was deﬁned as a primary or locally recurrent tumour
involving or abutting adjacent organs or structures (cT4) or palpa-
bly ﬁxed cT3 lesion. The eligibility criteria were as follows: patients
with unresectable primary rectal cancer or with an unresectable lo-
cal recurrence, pathologically proven adencarcinoma, nomore than
75 years of age, WHO performance status 62 in patients ﬁt for ma-
jor surgery and chemotherapy, lower border of tumour 615 cm
from anal verge, and signed informed written consent. Exclusion
criteria were as follows: distant metastases, tumour imaging indi-
cating that resection will never be possible even after chemoradia-
tion – for example tumour growth into S1–2, active coronary artery
disease, cardiac arrhythmia, congestive heart failure, previous
radiotherapy to the pelvis, history of peripheral neuropathy, and
history of cerebral stroke. Work-up included: colonoscopy or rec-
toscopy (if a colonoscopy was not carried out before treatment it
should be done within 3 months of surgery), pelvic MRI (alterna-
tively pelvic CT was allowed if MRI was not available), CT of the
abdomen, chest X-ray or CT, blood count and biochemistry. Other
examinations were carried out if necessary, for example cystoscopy
for a diagnosis of urinary bladder involvement.Neoadjuvant treatment
The patients were randomized to receive either preoperative
5  5 Gy irradiation over 5 days and consolidation chemotherapy
of three cycles of FOLFOX4 or 50.4 Gy in 28 fractions of 1.8 Gy over
5.5 weeks concomitantly with oxaliplatin, 5-ﬂuorouracil and leu-
covorin. The interval between the start of radiation and surgery
was the same (12 weeks) in both groups. Overall neoadjuvant
treatment time and the interval between completion of radiother-
apy/chemotherapy and surgery were about 6 weeks in both groups
(Fig. 1).
The irradiation technique was identical in both groups. The clin-
ical target volume (CTV) included the primary tumour with at least
15 mm margin, regional lymph node metastases, and uninvolvedregional nodes: mesorectal nodes with the upper limit set at the
sacral promontory, obturator, internal iliac and lower common
iliac nodes. Irradiation of external iliac nodes was not recom-
mended because there is no evidence indicating beneﬁt from such
treatment [16]. In case of a very low-lying lesion or when the anal
canal was involved, the lower border of the CTV was located at
least 2 cm distally from the tumour. Otherwise, the lower limit of
the CTV was located at the pelvic ﬂoor or at least 4 cm below the
lowest part of the tumour in case of a high lesion. A single fraction
boost dose of 4 Gy in the experimental group or 5.4 Gy in three
fractions in the control group was given in case of involvement
of lymph nodes (>1 cm) not routinely removed during surgery,
for example internal iliac or obturator nodes. A three-dimensional
planning and the use of at least a 6 MV linear accelerator were rec-
ommended. The dose was speciﬁed at the intersection of the axes
of the ﬁelds. In order to protect the small bowel, irradiation with a
distended urinary bladder was advised. A belly-board device was
also recommended.
Patients allocated to the experimental group received three cy-
cles of FOLFOX4. The ﬁrst cycle was planned to start a week after
the completion of radiation. However, in the case of radiation tox-
icity, the onset of chemotherapy was postponed until recovery.
Each cycle comprised a 2-h infusion of 85 mg/m2 of oxaliplatin
on day 1, given simultaneously with 200 mg/m2 of leucovorin
through a Y catheter. Next, a bolus of 400 mg/m2 5-Fu was given
and then 600 mg/m2 of 5-Fu in a 22-h continuous infusion every
14 days, for three cycles. If the second or third cycle of chemother-
apy was delayed, the interval between delivering the ﬁrst and last
dose of chemotherapy was limited to 7 weeks. Doses of chemo-
therapy which were not given within this time were missed. Pa-
tients allocated to the control group received two 5-day cycles of
5-Fu 325 mg/m2/day and leucovorin 20 mg/m2/day intravenous
bolus simultaneously with irradiation during the ﬁrst and ﬁfth
week of irradiation. Additionally, 5 one-day infusions of oxaliplatin
50 mg/m2 were given once a week at 1, 8, 15, 22, and 29 days of
irradiation. Postoperative chemotherapy in both groups was op-
tional. Early toxicity of neoadjuvant treatment was deﬁned as tox-
icity occurring during radio(chemo)therapy or within the interval
to surgery. In the experimental group, toxicity occurring during
irradiation, after irradiation (within interval between irradiation
and chemotherapy) and within or after chemotherapy was re-
corded separately. The NCI CTCAE v. 3 scale was used [17].Surgery
A second pelvic MRI or CT was not recommended routinely
prior to surgery as those examinations are not reliable in the
assessment of pathological response [18,19]. On clinical or radio-
logical examination persistent ﬁbrosis may mimic viable tumour
[18–20], and for this reason, the protocol stipulated that tumour
resection should be attempted regardless of clinical response. In
case of the involvement of neighbouring organs, multivisceral en
bloc resection was recommended. The extent of the resection had
to be decided at a multidisciplinary meeting based on a pre-treat-
ment pelvic MRI or CT. A favourable clinical tumour response did
not negate the need for an en bloc resection. This is because even
in case of a favourable response, cancer cells might be present in
the pre-treatment tumour volume. For tumours located in the
low or mid rectum, a total mesorectal excision was carried out,
and for tumours located in the upper rectum, a subtotal mesorectal
excision was done; i.e. the mesorectum was excised 4 cm below
the tumour. The distal bowel margin was at least 1 cm. Extraleva-
tor type of an abdominoperineal resection was required [21]. In the
case of an anterior resection, the decision to create a defunctioning
stoma was left to the surgeon. Enlarged internal iliac or external
iliac lymph nodes were resected. Resection was categorized as
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Fig. 1. Study design.
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1 mm from surgical margin. Macroscopically non-radical surgery
(R2) was conﬁrmed by a pathologist. Postoperative complications
were deﬁned as those occurring within 30 days after surgery.Pathology
The pathological examination was based on the Quirke method
[22]. The assessment of the circumferential resection margin
(CRM) was mandatory. Positive CRM was diagnosed when cancer
cells were seen within 1 mm of the surgical margin. Staging was
based on the 6th version of the UICC/AJCC TNM classiﬁcation. For
a diagnosis of complete tumour response, ﬁve samples had to be
taken from the pre-treatment tumour volume. If cancer was still
not found, an additional three slides had to be cut from each of
these samples. Pathological complete response was deﬁned as
the absence of cancer cells both at the primary site and regional
lymph nodes. Central quality control for radiotherapy, chemother-
apy, surgery, and pathology was not carried out.Statistics
A microscopically radical resection rate was chosen as the main
endpoint of the trial, because in the Nordic randomized study on
unresectable rectal cancer, this variable was shown to be corre-
lated with both, the type of neoadjuvant treatment and long-term
disease-free survival [2]. The assumed microscopically radical
resection rate in the conventionally fractionated chemoradiation
group was 75%. To detect at least a 10% beneﬁt in the short-course
group, 540 patients are needed assuming the use of two-sided chi-
square test with a signiﬁcance level of 0.05% and 80% power.
Randomization was performed by telephone to the central trial
ofﬁce and was based on the minimization method. The patients
were stratiﬁed according to the centre and type of the tumour (pri-
mary cT3 or cT4 or recurrent cancer). The trial is registered with
ClinicalTrials.gov number NCT00833131.
As little is known about toxicity of short-course radiation com-
bined with sequential chemotherapy, an interim analysis of the
ﬁrst 100 patients was planned. Apart from early toxicity, micro-
scopically radical resection rate and pathologic response to preop-
erative treatment were also evaluated, as one cannot exclude that
due to the lack of synergistic interaction (radiosensitization) be-
tween sequentially given chemotherapy and radiation in the
experimental arm, the tumourcidal effect may be inferior to that
produced by simultaneously given chemoradiation. Termination
of the study was planned in case of major differences between
the study groups in the above endpoints. The stopping rules were
not deﬁned. As the primary aim of the current interim analysis was
to assess toxicity, the analyses were performed according to theschedule of radiotherapy actually given. Statistical tests were not
performed as this was planned after the completion of accrual.Results
Between November 2008 and January 2010, 100 patients from
20 Polish hospitals were enrolled. Three patients were excluded,
49 patients received short-course irradiation with consolidation
chemotherapy and 48 patients received chemoradiation (Fig. 2).
The patients in both groups were well balanced with respect to
the pre-treatment characteristics (Table 1). The majority of pa-
tients (72%) had cT4 primary tumour.
Details of neoadjuvant treatment and surgery are given in Ta-
ble 2. All patients in the experimental group received the planned
total dose of irradiation, whereas, in the control group, the dose
was reduced in six patients (13%) due to toxicity. The toxic effect
of short-course radiation occurred more often after treatment (i.e.
during the one week interval between radiation and chemother-
apy) than during treatment (Table 2). Sacral pain was the most
common toxic effect occurring during irradiation, whereas diar-
rhoea and proctitis were the most common toxic effects occurring
after irradiation. Overall (both during and after short-course radi-
ation) grade 1–2 toxicity occurred in 26 patients (53%) and grade
3 toxicity (maximal) occurred in two patients (4%). Due to this
toxicity consolidation chemotherapy was postponed in four pa-
tients (8%). Intraoperative irradiation was not given in either
group.
The protocol stipulated the delivery of chemotherapy one week
after the completion of short-course radiation. However, it was
most often 10 days, as irradiation ended on a Friday and chemo-
therapy started on a Monday. Oxaliplatin was not given in 1 pa-
tient (2%) in the experimental group and in 7 patients (15%) in
the control group. Overall, grade 3 or higher acute toxicity of neo-
adjuvant treatment was recorded in 26% of patients in the experi-
mental group and in 25% in the control group (Table 2). Diarrhoea
and c toxicity were most common side effects in both groups.
There were two sudden deaths shortly after completion of chemo-
radiation in the control group, probably due to a thromboembolic
event. There were no toxic deaths in the experimental group. Che-
motherapy dose reduction (mostly oxaliplatin) due to toxicity was
needed less often in the experimental group than in the control
group (10% vs. 25% of patients). However, when both the need
for chemotherapy dose reduction and the need for chemotherapy
cycle delay were taken into account, the rates were similar - 26%
of patients in the experimental group and 25% in the control group.
This was because, in the experimental group chemotherapy could
be delayed, whereas in the control group, chemotherapy doses
not given during irradiation were missed.
Staging laparoscopy and laparoscopic ultrasound investigation
were not performed before embarking on excision. The overall
100 randomized patients
50 allocated to 5 x 5 Gy + chemotherapy
47 received allocated intervention   
3 received chemoradiation
50 allocated to chemoradiation
45 received allocated intervention
2 received 5 x 5 Gy + chemotherapy
3 excluded
1 did not meet the entry criteria
1 did not receive neoadjuvant treatment
1 received 5 x 5 Gy alone due to a cardiac 
infarction
49 received 5 x 5 Gy + chemotherapy 48 received chemoradiation
49 analysed 48 analysed
Fig. 2. Trial proﬁle.
Table 1
Patients’ characteristics.
5 + 5 Gy + chemotherapy N = 49 Chemoradiation N = 48
Gender
Female 16 (33) 15 (31)
Male 33 (67) 33 (69)
Age in years, median (range) 60 (35–74) 59 (28–74)
Type of tumour
Primary ﬁxed cT3 11 (22) 9(19)
Primary cT4 34 (69) 36 (75)
Recurrent 4 (8) 3 (6)
WHO performance score
0 23 (47) 22 (46)
1 24 (49) 24 (50)
2 2 (4) 2 (4)
Distance between tumour and anal verge in cm, median (range) 5 (1–14) 6 (0–15)
Pelvic MRI, performed
Yes 30 (61) 32 (68)
No 19 (39) 15 (32)
No data 1
Numbers in the table denote number of patients (%) unless otherwise stated.
174 Neoadjuvant treatment for unresectable rectal cancerresection rate and microscopically radical resection rate were 77%
and 73% in the experimental group vs. 83% and 71% in the control
group (Table 2). Postoperative complications were observed in 27%
of patients in the experimental group and in 16% of patients in the
control group; complications requiring re-operation were recorded
in 9% and 7% of patients, respectively. There was no postoperative
mortality in either group.
A pathological complete response was observed in 21% of pa-
tients in the experimental group and in 8% in the control group (Ta-
ble 3). A downstaging effect was observed in 71% and 73% of
patients, respectively. A positive circumferential margin was re-
corded in 5% and 15% of patients, respectively. A distal bowel mar-
gin was negative in all patients.Discussion
The interim analysis revealed no major differences in acute tox-
icity and local efﬁcacy between the two evaluated neoadjuvant
treatments. So, the trial is continued. Our data contribute to the
growing evidence showing that short-course radiation combined
with consolidation chemotherapy is a promising management
[11–15]. This opinion is, however, based mainly on the earlyassessment of efﬁcacy, namely on the radical resection rate and
on the rate of pathological complete response (Table 4). Long-term
oncological results are unknown as they were reported only in 15
patients [11]. More data are available for the short-course preoper-
ative radiation with long interval to surgery; encouraging local
control was observed [6,8,11].
Most of the acute toxicity of short-course irradiation, usually
grades 1–2, is delayed for a few days after its delivery [23]. This
toxicity occurred in approximately half of the patients. Such toxic-
ity is not observed when surgery takes place immediately after the
delivery of 5  5 Gy. This is because the rectum (the organ at risk of
acute adverse effect) is excised before damage occurs.
A week point of the trial is that initial pelvic MRI was not used
in all patients (only in 64%, Table 1). This was because, in Poland
in many centres there is a long waiting list for this examination.
For this reason, palpably ﬁxed cT3 lesion was used as the entry
criterion instead of threatened mesorectal fascia diagnosed by
using MRI. It should be stressed that tumour ﬁxity is not always
representative of very locally advanced unresectable lesion. Other
weakness of the study is that administration of cetuximab or bev-
acizumab was not considered in patients with recurrent tumour.
A drawback of the study design is a lack of strictly predeﬁned
Table 2
Treatment related parameters.
5 + 5 Gy + chemotherapy N = 49 Chemoradiation N = 48
Radiotherapy dose reduction due to toxicity
Yes 0 (0) 6 (13)
No 49 (100) 41 (87)
Chemotherapy dose reduction due to toxicity
Yes 5 (10) 12 (25)
No 44 (90) 36 (75)
Chemotherapy cycle delay due to toxicity (without dose reduction)
Yes 8 (16) n.a.b
No 41 (84)
Chemotherapy dose reduction or delay due to toxicity
Yes 13 (26) 12 (25)
No 36 (74) 36 (75)
Grade of toxicity occurring during 5  5 Gy n.a.
0 35 (71)
1 7 (14)
2 7 (14)
3 0
4 0
Grade of toxicity occurring during interval between 5  5 Gy and chemotherapy n.a.
0 26 (53)
1 10 (20)
2 11 (22)
3 2 (4)
4 0
Grade of toxicity of consolidation chemotherapy n.a.
0 25 (51)
1 6 (12)
2 6 (12)
3 9 (18)
4 3 (6)
Grade of overall neoadjuvant treatment toxicity
0 11 (22) 4 (8)
1 10 (20) 10 (21)
2 15 (31) 22 (46)
3 10 (20) 8 (17)
4 3 (6) 2 (4)
Toxic deaths 0 2 (4)
Overall neoadjuvant treatment time in weeks, median (range) 6.6 (1.9–16.6) 5.4 (4.1–6.7)
Interval between completion of 5  5 Gy and start of chemotherapy, median (range) 10 (5–35)c n.a.
Interval between start of radiation and surgery in weeks, median (range) 12.0 (9.4–25.3) 12.3 (10.4–48.1)
Surgery
Not performeda 4 (8) 4 (8)
Exploratory laparotomy; pelvic tumour was still unresectable 6 (12) 4 (8)
Exploratory laparotomy; distant metastases were found at surgery 1 (2) 0
R2 resection 0 1 (2)
Microscopically non-radical resection 2 (4) 5 (10)
Microscopically radical resection 36 (73) 34 (71)
Adjacent organs were resected
Yes 14 (37) 17 (43)
No 24 (63) 23 (57)
No tumour resection 11 8
Type of surgery
Anterior resection 14 (37) 19 (48)
Abdominoperineal resection 15 (39) 16 (40)
Hartmann’s procedure 9 (24) 5 (12)
No tumour resection 11 8
Postoperative complications
Requiring re-operation 4 (9) 3 (7)
Treated conservatively 8 (18) 4 (9)
No complications 33 (73) 36 (84)
No data – 1
No surgery 4 4
Hospital stay post surgery in days, median (range) 8.0 (5–23) 8.5 (4–50)
No data 3 6
Numbers in the table denote number of patients (%) unless otherwise stated.
Abbreviation use: n.a., no applicable.
a Surgery was not carried out for the following reasons: the experimental group – in two patients distant metastases were detected after neoadjuvant treatment and two
patients did not consent for surgery; the control group – two patients died shortly after chemoradiation and two patients did not consent for surgery.
b Delay of chemotherapy was not allowed by the protocol; all chemotherapy had to be given during irradiation
c Interval between completion of 5  5 Gy and start of chemotherapy longer than two weeks was recorded in 7 patients (15%).
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Table 3
Pathology.
5 + 5 Gy + chemotherapy
N = 38
Chemoradiation
N = 40
ypT category
T0 (complete response) 8 (21) 3 (8)
T1 0 2 (5)
T2 4 (10) 11 (27)
T3 19 (50) 15 (38)
T4 7 (18) 9 (22)
Downstaging effect in the primary tumour
Yes 24 (71) 27 (73)
No 10 (29) 10 (27)
No applicable, recurrent
tumour
4 3
Number of lymph nodes
found, median, (range)
10 (0–39) 8 (0–30)
ypN category
N0 28 (74) 22 (55)
N1 7 (18) 10 (25)
N2 3 (8) 8 (20)
Circumferential resection
margin 61 mm
2 (5) 6 (15)
Circumferential resection
margin >1 mm
36 (95) 34 (85)
Table 4
Short-course radiotherapy and long interval to surgery in advanced rectal cancer. The
rate of pathological complete response in relation to the delivery of consolidation
chemotherapy.
5  5 Gy alone 5  5 Gy + chemotherapy
Stockholm III trial
[9]
15/120
(12.5)
Widder [15] 2/2
Lithuanian trial [7] 1/37 (3) Radu [11] 2/9
Pettersson [10] 7/109 (6.4) Shin [13] 1/6
Hatﬁeld [6] 2/24 (8) Myerson [12] 6/23 (26)
Pach [8] 8/77 (10) Van Dijk [14] 9/40 (23)
Radu [11] 2/28 (7) Current study 8/38 (21)
Total 35/395
(8.9)
Total 28/118
(23.7)
Numbers in the table denote: number of patients with pathological complete
response/total number of patients (%).
176 Neoadjuvant treatment for unresectable rectal cancerstopping rules for interim analysis. Other weak point of the study
design is the uncertainty whether the addition of chemotherapy
to short-course radiation improves local efﬁcacy. In order to an-
swer this question, a literature search was carried out. Patholog-
ical complete response in patients with advanced rectal cancer
treated with short-course radiation and long interval to surgery
[6–11] was compared to pathological complete response after
short-course radiation combined with consolidation chemother-
apy [11–15]. Pooled results showed 8.9% of pathological complete
response in patients treated with short-course radiation alone
and 23.7% in patients treated with combination of short-course
radiation and consolidation chemotherapy, chi-square p < 0.001
(Table 4). Thus, this cross-study comparison suggests a beneﬁcial
effect of the addition of chemotherapy. Another uncertain point
of the study design is the addition of oxaliplatin to 5-Fu based
chemotherapy when combined with radiation. At the time the
protocol was being written, a panel of experts proposed the addi-
tion of oxaliplatin to chemoradiation for unresectable rectal can-
cer [24]. The rationale for such a proposal was that this strategy
may lead to a higher regression rate and thus a higher resectabil-
ity. Results of four randomized trials comparing ﬂuoropyrimi-
dine-based chemoradiation with or without oxaliplatin wererecently published [25–29]. In three of these trials acute toxicity
increased with oxaliplatin addition without apparent beneﬁt in
terms of pathological complete response [25,26,29]. In only one
trial which provided follow-up observations, no long-term beneﬁt
of oxaliplatin was found [27]. It should be noted, however, that
all four trials were carried out in resectable rectal cancer. In con-
trast to the aforementioned randomized trials, a retrospective
analysis of a series of patients with unresectable cancer sug-
gested beneﬁt in cancer speciﬁc survival with addition of oxalipl-
atin to chemoradiation [3]. Thus, the role of oxaliplatin in
unresectable rectal cancer is still uncertain.
In conclusion, our interim analysis suggests that early results
after short-course irradiation and consolidation chemotherapy in
unresectable rectal cancer are not worse than those achieved after
conventionally fractionated chemoradiation. Thus, short-course
irradiation and consolidation chemotherapy may be considered
in a case of logistic problems; for example a long waiting list for
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